Carter’s (CRI) dropped more than 21% today because, even though it beat Q4 expectations on both sales and earnings, management issued a much weaker 2026 earnings outlook, highlighted ongoing margin pressure from tariffs and product costs, and guided to a sharp near‑term EPS drop that jarred investors.
Q4 2025 sales were about 925 million dollars, beating estimates and up mid‑single digits year over year (helped by an extra week), and adjusted EPS of 1.90 dollars topped the roughly 1.55–1.60 dollar consensus.
Despite this beat, adjusted EPS fell 20.5% from last year, and operating margin compressed by about 50 basis points to 9.2% as higher tariffs, product costs, and incentives ate into profitability.
For 2026, management guided to a low double‑digit to mid‑teens decline in adjusted EPS from 3.47 dollars in 2025 and forecast Q1 EPS of just 0.02–0.08 dollars versus 0.66 dollars last year, far below Wall Street expectations.
Higher tariffs, mix shifts, weaker cash flow (2025 operating cash flow dropped to 122 million dollars from 299 million), and lingering wholesale and retail pressures fed worries that Carter’s earnings power is structurally lower than before.
Carter’s delivered a headline beat in Q4 2025. Revenue came in around 925 million dollars, up roughly 7–8% year over year and above consensus near 904 million dollars, with growth across U.S. retail, international, and wholesale. Part of that growth reflected a 53rd week in the fiscal year, which management said added about 37 million dollars of sales, so underlying growth was closer to 3–4%.
Adjusted EPS was 1.90 dollars, handily beating expectations of roughly 1.55–1.60 dollars. Operating income ticked up about 1.8% to roughly 84.7 million dollars, but the operating margin slipped to 9.2% from 9.7% as the company absorbed higher input costs and tariffs. On a full‑year basis, revenue rose to about 2.9 billion dollars, yet GAAP diluted EPS dropped to 2.53 dollars from 5.12, and adjusted EPS fell to 3.47 dollars, underscoring how much profitability has compressed even as sales held up.
The real problem was what Carter’s said about the future. Management guided 2026 adjusted EPS to about 2.91 dollars, implying a low double‑digit to mid‑teens percentage decline from 3.47 dollars in 2025, even though they expect low‑ to mid‑single‑digit net sales growth. In practical terms, that means revenue may inch up, but rising costs and tariffs will continue to squeeze profits.
The near‑term outlook was even more jarring. For Q1 2026, Carter’s projected adjusted EPS of just 0.02–0.08 dollars, compared with 0.66 dollars in the prior‑year quarter and consensus near 0.36 dollars—one of the largest negative EPS guide gaps in the consumer space this season. Management cited higher tariffs, elevated product costs as they invest in product “make,” promotional intensity, and deleverage in both U.S. retail and wholesale as key headwinds.
Investors had already been wrestling with conflicting analyst views: some saw Carter’s as a value play, while others warned that longer‑term forecasts point to flat‑to‑down revenue and significantly lower earnings by 2028. Today’s guidance effectively endorsed the more pessimistic camp, confirming that margin and EPS pressures are not just a 2025 blip.
Beyond EPS guidance, several underlying trends raised red flags. Adjusted operating income for 2025 fell by about 26 million dollars, and the adjusted operating margin dropped from roughly 13.4% to 9.7%, driven largely by lower profitability in U.S. retail and wholesale segments. Management highlighted the “lion’s share” of the decline came from higher tariffs and product costs, along with wage and incentive pressures.
Cash flow also deteriorated meaningfully. Operating cash flow fell to roughly 122 million dollars in 2025 from about 299 million dollars the year before, mainly due to higher inventories and reduced earnings. That weaker cash generation, combined with refinancing activity and a new 750‑million‑dollar asset‑based revolver, reinforced the sense that Carter’s is operating with less financial flexibility than in the past.
Although management is executing productivity actions—cutting about 300 office jobs, planning roughly 150 store closures over three years, and targeting 35 million dollars in annual savings plus more than 10 million dollars in SG&A cuts—those benefits will take time to fully materialize and may be partially offset by ongoing cost and tariff headwinds.
When you combine a Q4 beat with:
A 20% year‑over‑year drop in adjusted EPS,
A big decline in operating and cash‑flow margins, and
A 2026 EPS outlook that calls for another low‑teens percentage decline,
you get a classic “good quarter, bad future” setup.
Traders quickly repriced CRI to reflect structurally lower earnings power. The stock slid from the mid‑40s into the low‑30s, a drop of more than 20%, putting it near its 52‑week lows despite what appears, at first glance, to be solid holiday‑quarter results. In short, Carter’s didn’t fall because Q4 was weak; it fell because management confirmed that profits are likely to keep shrinking in 2026, and the market is no longer willing to ignore that reality.
Tickeron AI Perspective
The 10-day moving average for CRI crossed bearishly below the 50-day moving average on March 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for CRI moved out of overbought territory on February 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on February 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRI as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CRI turned negative on February 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .
CRI moved below its 50-day moving average on February 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRI advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .
CRI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 191 cases where CRI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.336) is normal, around the industry mean (5.941). P/E Ratio (13.423) is within average values for comparable stocks, (26.665). CRI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.238). Dividend Yield (0.046) settles around the average of (0.030) among similar stocks. P/S Ratio (0.415) is also within normal values, averaging (2.260).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of apparel and related products for babies and young children
Industry ApparelFootwearRetail